CRYSTALLINE PPAR-DELTA AGONIST

Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by admin...

Full description

Saved in:
Bibliographic Details
Main Authors SULEIMAN, OSAMA, SHARP, EMMA, MACRAE, JULIE, DEL RIO GANCEDO, SUSANA, FEEDER, NEIL, LEE, RACHAEL, BALOGH, CRISTINA
Format Patent
LanguageEnglish
French
Published 27.01.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online AccessGet full text

Cover

More Information
Summary:Described herein is crystalline sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate, uses of such crystalline material in the preparation of pharmaceutical compositions for the treatment of diseases or conditions that would benefit by administration with a PPAR? agonist compound. L'invention concerne un (E)-2-(4-((3-(4-fluorophényl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phényl)allyl)oxy)-2-méthylphénoxy)acétate de sodium cristallin, des utilisations de ce matériau cristallin dans la préparation de compositions pharmaceutiques pour le traitement de maladies ou d'affections qui en bénéficieraient par l'administration d'un composé agoniste de PPAR?.
Bibliography:Application Number: CA20213185909